Latest news with #CMPX
Business Insider
5 days ago
- Business
- Business Insider
Compass Therapeutics (CMPX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on Compass Therapeutics today and set a price target of $11.00. The company's shares opened today at $2.66. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Willey covers the Healthcare sector, focusing on stocks such as Incyte, Bicara Therapeutics Inc., and Exelixis. According to TipRanks, Willey has an average return of 2.0% and a 40.34% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Compass Therapeutics with a $13.20 average price target, which is a 396.24% upside from current levels. In a report released on July 1, Raymond James also initiated coverage with a Buy rating on the stock with a $9.00 price target. CMPX market cap is currently $373.4M and has a P/E ratio of -6.74. Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMPX in relation to earlier this year. Most recently, in May 2025, Thomas Schuetz, the CEO of CMPX bought 10,000.00 shares for a total of $21,100.00.
Yahoo
02-03-2025
- Business
- Yahoo
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025
We recently published an article titled . In this article, we are going to take a look at where Compass Therapeutics, Inc. (NASDAQ:CMPX) stands against the other biotech stocks. No matter the market environment, you'll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or break your portfolio in a very small amount of time due to the nature of how important clinical trial results are for these companies. The United Nations forecasts that the over-65 age group will grow by 150% from 800 million in 2024 to 2 billion by 2067. This "older, richer & sicker" population is expected to push global healthcare spending on medicines up 12% to $2.3 trillion by 2028. If you combine that with AI making breakthroughs in healthcare more frequent, you'll see many more biotech stocks starting to pop to the upside over the coming years. For this article, I screened the top-performing biotech stocks year-to-date. I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A biopharmacist holding a magnifying glass up against a microscope lens, studying a biological sample. Number of Hedge Fund Holders In Q4 2024: 14 Compass Therapeutics, Inc. (NASDAQ:CMPX) is a biopharmaceutical company that makes antibody-based therapies for several diseases. The stock is up significantly so far in 2025 due to it reporting 2024 results and its anticipated top-line Phase 2/3 data readout for COMPANION-002, which is evaluating tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC). It is expected by the end of the first quarter of 2025. In addition, Compass Therapeutics announced in January 2025 that it is advancing a new drug candidate, CTX-10726, a PD-1 x VEGF-A bispecific antibody, with IND submission expected by the end of 2025. The consensus price target of $11.38 implies 289.55% upside. Compass Therapeutics, Inc. (NASDAQ:CMPX) is up 101.38% year-to-date. Overall CMPX ranks 2nd on our list of the biotech stocks that are skyrocketing so far in 2025. While we acknowledge the potential of CMPX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CMPX but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: Why These 15 E-Commerce Stocks Are Skyrocketing So Far In 2025 and Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
